Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V
Report documents
-
Extract of dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V
-
Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V
Press releases
Sofosbuvir/velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications
Historical comparisons and considerations of individual study arms unsuitable for conclusions on the other research questions
Additional information
Federal Joint Committee (G-BA)
2017-01-05 A G-BA decision was published.
Project details
- Project no.
- A16-48
- Commission
- Commission awarded on 13.07.2016 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48
Status: Commission completed
-
Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed